Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Quest Partners LLC

Quest Partners LLC trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,137 shares of the life sciences company’s stock after selling 360 shares during the period. Quest Partners LLC’s holdings in Illumina were worth $409,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Versant Capital Management Inc raised its holdings in Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina during the 2nd quarter worth $34,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Illumina in the 2nd quarter worth about $61,000. Finally, Mizuho Securities Co. Ltd. acquired a new stake in Illumina in the 2nd quarter valued at about $63,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 2.3 %

ILMN opened at $140.14 on Monday. Illumina, Inc. has a 1 year low of $93.51 and a 1 year high of $156.66. The firm has a 50 day moving average price of $140.61 and a 200 day moving average price of $124.94. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company has a market cap of $22.23 billion, a PE ratio of -14.07 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter last year, the firm posted $0.33 EPS. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. Sell-side analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

ILMN has been the topic of several recent research reports. JPMorgan Chase & Co. upped their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. TD Cowen increased their target price on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Daiwa America raised Illumina to a “strong-buy” rating in a report on Friday, August 16th. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research note on Wednesday, August 28th. Finally, Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.